NÆÈè30`40 ng/l ÆÈÁ½DtÌjR`nWjZxÉäáµÄSÍOl70/min ©çÅiÍzÂnÉ}«¨æÑ«Ì«e¿ðyÚ·D}«øÊÍiÉº¤@\áQÅå100/min ÉÜÅÁµ½D1976NÉÍiéD«Éº¢mGsltCGsltÌtZ

ÌiKµÍ@\áQÌÝÈç¸\¢ÌÙíÆµxªÁµCSÁÎ©èÅÈ­ûkú¨æÄ®¬d»Æ¢¤dåÈaÏ»ð­Ç·éDöÑg£ú³àÁ·é±Æª¾ç©É³êÄ¢Ý«¨æÑ°«Ì«e¿Åé3) D±Ìæ¤ÈÏ»Íð´_oóeÌÕfòéD«aÔÉ}«øÊªdÈè[Èaóðæ·éêà«S¾³âÂÇ«®¬d»ÇÈÇÅéDpropranolol ¨æÑ phentolamine Ì^Éæè}§³ê½DjR`ªð´_oðhµÇðûéD

½Î±ÌÉÍ3,000íÞÈãÌ³Ü´ÜÈ¬k³¹é±Æð¦µ½DªªÜÜêéDzÂnÉe¿ðyÚ·i¨¿Æ

1964NCKershbaum çÍ52ÎÌSØ[ÇãµÄCjR`Cê_»YfCê_»fCVA«áÉ^oR 2 {ði³¹tÌV£b»fC«_fCñ_»YfCñ_»fÈ_iFFAjZxÌÚð¢µ½4)D»ÌZxÍÇð°é±ÆªÅ«æ¤1)D±Ì¤¿Äzíniã 1 ÔÈãÉí½èlð¦µ½Dv

ðîµÄzü³êzÂnÉ«e¿ðyÚ·åvÈ56ÇáÌ¢Åà¯lÌÊª¾çêÄ¢éD¬ªÍCjR`¨æÑê_»YfÅ

é8,9)DV£b_Ìã¸Í LDL RXe[ÌÁÆ HDL RXe[Ìáºðµ«C·úIÉ®¬d»ð£i·éºnÆÈéD}«øÊA.

ç©¶ßð´_oßÕfò trimetaphan ð^·éÆV£b_Ìã¸Í}~³êé±Æà¦³êÄ¢éDÇ¯½ïiÉº¤tÌjR`ZxÌÚªÍ¶ßÄñ³ê½ÌÍ1975NÅé2) Djí C_14

B.

ê_»YfiCOjÅxµ½jR`ðÜÞ^oRªì»³ê 4zÂnÌê`IÈðÍ oxygen transporti}¼Ìí±Òª±Ì^oRðiµ½Di 1 {PjCxªåC©çæèñ¾_fðÌàgDÉæéjR`Ì®¬ZxÍ10ªãÉs[³çÉ×Eà~gRhAÜÅèÍ¯é±Æ

mKey words ni#zÂn#«S¾³
ú{zÂíwïêåãzÂíêåãæACªæQ B@@ENXCCC}P

oxygen cascade: oxygen transport g hemoglobin mði¶£ 5 æèøp)é5)DwOrÌ_f\ªdvÅi·éO¨æÑ¼ãÌ¥zÂ®Ôð¢µéDiÉæèzü³ê½ê_»YfÍwO½6)Dñè^¹ÉÇóQÈÇÅ¥®¬¢e@ð{ÅrÆ·éDiÌöxÉàæéªñiÒsµ½ª¾ç©È·ó«aÏÌÈ¢³Ò11¼ð

Ì 2 {È¢µ 6 {öxÌê_»YfwOrÎÛÆµ½DSÌåC³Ìã¸Æ¥®¬ª`¬³êéD_f^À\ªáº·é±ÆÍ¢ÊÌÇak¬ðFß½D¥®¬àhv¤ÜÅàÈ¢D¬¬vðp¢Äªèµ½¥¬\õ\C·Èí¿sNj« 6 ¼Å©]ÔGS[^Éæé^coronary ow reserve (hyperemic ow velocity­®×ðs¢iúÆñiúÌ·ð¢µresting ow velocity)/resting ow velocity Íá½6)Dall­out ÜÅiKIÈ×±Åºµ½i}QjD¥Ã¬´Ì¬Ê©ç¥¬\éD×Éº¤ double productiS~³jÌÁÉõ\ðvªµ½¬ÑàÍ·ªÈ©Á½ªC×ÉæétÌû_Zx«iÒÅÍ¥¬\õ\ªáºµÄ¢éDiÌÁÍCiúÌÙ¤ª¢±Æª¾ç©É³

Êª½¢ÙÇáº·é±Æà¦³ê½D

ê½D³çÉ all­out ÜÅÌ^®sÂ\Ôðiª¬ÂÃWÌ´iCtBum[QÁÈÇtÃÅnÉe¿µðð`¬·éø«àär·éÆiúÉÍZkµÄ¢½DÆÈéÂ\«àC.

é7)DñiÒÉä×éDvX^OWnÖÌÖ^àmçêé6)D¥zÂwme¿jR`ÍJeR~ÌV£ðhµC³ã¸ÆSÁð«½µSØ_fÁïÊðå·éD³çÉ¥ÇÌg[ðß¬ïRðµC¥¬\õ\àáº³¹é6)D^oRð 1 {CCD

ú{zÂíwïêåãiKµiKµÍ¥®¬¾³Ìë¯öqÌêÂÅzÂíêåãæACªæQ B@@ENXé8`11)DA Report Surgeon General #CDC 89_8411 É æ ê Î C Ä  Å Í Â ¢ Å ß Ü Å i  Ò
5,000lCÖAµ½ premature deaths ÍNÔ39lÆè³êÄ¢½D»ÝÅÍå«ÈÐïIC­¡IÈâèÆÈèi@Ù»ÉÜÅ­WµÄ¢éDiÆÖAµ½SÍS¢EÅNÔè250lÉàÈéDíª{ÌvÉæêÎ1990Nã
Í¶ßÉÍ¬lj«Ìi¦61÷CßNÅàÈ¨50÷ð´¦éªñ³êÄ¢éD«Ìi¦CÆ­É20ãÌ«Ì»êÍÞµëÁÌXüÉ

èCÙÚ20÷Ìª¦³êÄ¢éD¢ÄÉ¨¯é FRISC_2, TIMI_VB, VANQWISH ÈÇÌ³ì×åKÍÕ°±ÅÍQÁÇáÌi¦ª30`43÷Æ³êÄ¢é12) DæiÌÅíªÉ¨¯éi¦ÍoµÄ¢DiªíªÉ¨¯éÅåÌ¥ë¯öqÅéÆ¢ÁÄàß¾ÅÍÈ¢DÆ­ÉáN­ÇÌ«S¾³³ÒÅÍÇÆÀÔë¯öqÅij¥¬\õ\máºi¥®¬¾³mAÇájIP¢jiCAi¶£ 6 æèøpjéi}P)6)Dè·éöqà®³êÄ¢é17)D«aÔg}«øÊA.

}QiÆ±êçvöªÇÌæ¤ÉÖíéÌ©Õ°®¬d»gSØáÅ¼ÚØ¾µ½¬ÑÍÈ¢Dµ©µiÆÌÖßNC®¬d»Ì¶¬@ªð¾³êÂÂAðª·é±ÆÍÂ\ÅéDv[NÌÀèé12) DiKµÉº¤jR`ÛæÍ®¬d»«ÉyÚ·«e¿Í³ã¸CSåÅð£iµCÆ«É¥®¬àoð·ó·éDiÉé6) D³Íûkú¨æÑg£úÆàÉå·æè³ªã¸µSªÁ·éÆSØ_fÁéDv[NjôÉº¤ð`¬ÉÂ¢ÄÍCïÊÍå·éD¥·óÇáÅÍSØ­¶Ì¬ÂÃWÌ´iCtBum[QÁð··lC¢íäé¥¬\õ\ª³çÉáº·éDéD¥®¬àÌ¬ÂðÌ`¬15) ÉÍC®¬^oR·SÇÆÄÎêéaÔªÝçêéæ¤ÉiÇÌàçCR[QÆ÷Ì von Willebrandª·SÉ­ìðU­µâ·­·é±Æàmçêfactor ÌÝìpªdvÈððS¤D¬ÂÌéDSØÍÆ«ÉvIs®¬ðäNµËR«»É` GPUb/Va, GPTb ÈÇàÖíéÌ´öÆÈé±Æàé9,13)D±Æª¾ç©É³êÄ¢é15,16)DiÍ®¬d»ð£iµCv[NjôÉÛµB.

}«¥ÇóQÄ¬ÂðÌ`¬ð£i·éD}«¥ÇóQðÅßC}«¥ÇóQÌaÔªÚ×Éð¾³êÄ

äN·é·ú¨æÑ}«úÌvöÆµÄdvÅ«½14) D­ÇÌîÕÆµÄ®¬d»Ì¶ÝªéD¥ÂÇÌx¢ÍðÌå«³ÈÇÉæèÏdvÅ»·éªC¢¸êÉ¹æ¬ðjQ·éDSØéD®¬d»Éº¤v[NÌ­¶ÆjôCð­ÇÌ@àªq¶½ÈwÌxÅðÌlªÏ»µ^®Ïe\Ée¿ðyÚ·Ds¾³êÄ«½15,16)D®¬d»v[NÌÀè«ðÀè·SÇÆÄÎêé²Æ­CÀÃCJì³Kè·éöqCv[NjôÉº¤ð`¬ðKÜ´ÜÈóµÅeÕÉ·SÉªU­³êéD®S

ú{zÂíwïêåãzÂíêåãæACªæQ B@@ENXCCE}R

Framingham Study jIPig«S¾³m­Çpxij«)i¶£ 9 æèøpjª ¾ ç ê Ä ¢ é10) D 20 Î ã © ç 30 Î ã Ì á ÒÂÇÍ}«SØ[ÇðäN·éD3,366lÉÂ¢ÄS´¹g¸@ÉæèSÌ@ \ Æ i  Ì Ö A ð  ¢ µ ½ CARDIA Study«S¾³jÖ EBMi1995NjÅÍCñiÒÉä×iÒÅÍÀÃ¥®¬¢e@Éæè«S¾³ðmèffµÌSª­¶ºSØ mass Ìå«¢±Æª½A±1,000ÇáÉÂ¢Äiðð20Îã©ç70¦³êÄ¢é20) D®¬g`ÌðÍ©ç^oR 1ÎãÜÅNîÅwÊ»µ½6)DáNÇáÙÇi{ðz¤ÆÇÌ stiness ªå·é±Æà¦ÒÌªå«­CîÒÅÍ»Ìpxªáº·³êÄ¢é21) D³çÉiÒÆñiÒÌÇéDáNÒÙÇiÍdvÈë¯öqÅéDàç@\ðOr¬ÊÉæèär¢µ½¬ÑîÒÅÍiÎ©èÅÈ­»ÌÙ©Ìë¯öqâÅÍCiÒÅ acetylcholine ÉÎ·é¬ÊÁîªÖ^·éª¢DúJÈ¤ÇÉæéÁ½ªáºµÄ¢é±ÆCallopurinol Éæé40`50Îã 4 lð10NÔÇÕ²¸µ½¬ÑÅxanthine oxidase ÌjQÉæèÇàç@\ªñÍCiÒÌzÂí¾³ÉæéSpxªñi·é±Æª¾ç©É³êÄ¢é22)DÒÉä×Cj«1.4{C«2.7{Åé±Æð¾ç©Éµ½18)DÖg\mÕ°¬ÑÄÌ Framingham Studyi1984NjÉæéu
w²¸Ì¬Ñ9)ÅÍCiÒÌSØ[Ç­ÇpxiKµÌ«S¾³ÉÖíéQÍL­mçÍñiÒÉä× 3 {ÈãCËRÍ 7 {ÈãCêé23) Di{Æ¾³pxÌ«S¾³ÉæéSpxÍ 2 {ÈãÅªÁ¢¾ÉÍÖéD³çÉ¼Ì¥¾³ë¯öqðº¤©Û©

½Dµ©µ·SÇÌ­ÇpxÉÍ·ªÈ©Á½DÅpxÍÙÈéDlj«ÌêCë¯öqðà«S¾³ÉæéSCËRÌpxÍiÊ½È¢êÉä×CiÒÅÍ 2 {CiÉÁ¦ª½¢ÙÇÁµ½19) DXEF[fÌNjRXe[ÇÜ½Í³Ì

«7,495lðÎÛÆµ½iÒCñiÒÌär

4 {C³çÉiC³CRXe[± Goeteborg Studyi1988NjÅàÞÌ¬ÑÇÌ·×ÄðàÂÒÅÍ10{Ìë¯¦ÆÈéDCCF

ú{zÂíwïêåãzÂíêåãæACªæQ B@@ENXéÒÅÍ}SzÂnjy{Xim}«øÊgiKµ____FÇóÌU­vöÆÈéi¶£30æèøpjÐÆ½ÑSØ[Çð­Çµ½ÇáÅñ\hÌÏ_©çCið~µ½êÌbgÉÂ¢Ä¢µ½¬Ñàé24) DCASS Registry Ìo´·é¬ÑÆµÄCú{¹¾³wïïõÌAP[g²¸¬Ñi1990Njªé27) DïõÌi¦Í{vÉæéú{lÌi¦Ìñ¼^³ÒÌ¤¿55ÎÈãÌñÖÒ1,086áÆÖÅÒ807áÌ 6 NÔÌärÅÍCñÖÒÌSpcÅà30÷Oãªiµ±¯Ä¢éÆÌÊÅ

xÍ1.7{i95÷MÀE1.4`2.0jC[ÇÄ­¨æÑSÌXNÍ1.5{i1.2`1.7jÅÁ½DNîª­ÈÁÄàÖÌøÊÍ¯lÅ

Á½D

Á½DiÌ¾Qð\ñªÉ³mµÄ¢éWéD±Ì¬ÑÍu³çÉæéÖvÆÍÊÌÖ

èiÌKv«ð¦µÄ¢éDïÌIû@ÆµÄCßNÖãµÎç­ÌjRÖÌRXgÆøÊÉÂ¢Äà¢³êCÖv`ÖfÇóðÉa·é½ßCjR`ðÜñ¾OðÀs·é±ÆÉæèïpÌß¸àÂ\Kâpb`ÈÇªÝçêÄ«½28) DçÉÆ_³êÄ¢é25) DÖÉæéë¯¦áºÍ\t·éjR`pb`ðp¢½ÖÌÝÅÍáNáÙÇ°ÅLp«ªñdÓ@Éæè¦³ê½DíªÅàèC65`74ÎÅÍñÖáÆi~áÉ·ªÈ¢ÆÌ¬Ñàé26)DæÉyµÄ¢éDP É active smoker © g Î © è Å È ­ ü Ó Ìpassive smoker ÉÜÅ«e¿ÌyÔ±ÆªwE³êÄ¢éDµ©µiKµð~ßéÉÂ¢Ä}gé¢ÍwÍÉæiKµÍ}«¨æÑ«Ìe¿Éæè«ÁÄ¢éDÖÌ¢ïÈÒà½¢D³ç[ÖÉæS¾³Ì´öÆÈéi}S)29,30)DÆ­É}«¥èÇÌ­ç¢ÜÅÖøÊªúÒÅ«éÌ©ð¦ÇóQâËRðäN·éë¯vöÆÊuÃ¯éÍCàÁÏçiÒ©gÌ©oú{zÂíwïêåãzÂíêåãæACªæQ B@@ENXCCG

±ÆªÅ«æ¤Di³ê½¬ªÌàÅjR`¨æÑê_»Yfªå½éìp¨¿Å¶q17) Libby P, Ganz P, Frederick J et al: Vascular biology ofthe acute coronary syndromes. Acute Coronary Syn­éDdromes, ed by Topol EJ, Marcel Dekker Inc, NewYork, 1998, p1_20£q1) iÆNâèÉÖ·é¢ïF½Î±Ì¬ªDi18) ú¶J­È²¸¤ÇFiÒÌS¦Dú{oÏV·C[§C2002/2/719) Kannel BW: Update on the role of cigarete smoking inÆNCÛ¯lÐCC2002, p37_50
2) Armitage AK, Dollery CT, George CF et al: Absorptionand metabolism of nicotine frome cigarettes. Br Med Jcoronary artery disease. Am Heart J 1981; 101: 319_32820) Gidding SS, Xie X, Liu K et al: Cardiac function in1975; 4: 313_3163) Cryer PE, Haymond MW, Santiago JV et al:
Norepinephrine and epinephrine release and adrener­
gic mediation of smoking­associated hemodynamic andmetabolic events. N Engl J Med 1976; 295: 573_573
4) Kershbaum A, Bellet S: Cigarette smoking and bloodsmokers and nonsmokers: the CARDIA Study. J Am
Coll Cardiol 1995; 26: 211_21621) Muhmud A, Feely J: Eect of smoking on arterial sti­ness and pulse pressure amplication. Hypertension
2003; 41: 183_18722) Guthikonda S, Sinkey C, Barenz T et al: Xanthine oxi­lipids. JAMA 1964; 187: 132_1365) West JW: Respiratory physiology, 4th Ed, Williams &dase inhibition reverses endothelial dysfunction inheavy smokers. Circulation 2003; 107: 416_421

Wilkins, Philadelphia, 1990, p55³Cå¼Ë½Ù©FiÆ Cardio­23) Holbrook JH, Grundy SM, Hennekens CH et al:vascular diseases ÌÖADú¹¾ï 1991; 29: 206_Cigarette smoking and cardiovascular diseases: a state­

210

ment for health professionals by a task force appointed6) ¼crVîCRè7) Klein LW, Pichard AD, Holt J et al: Eects of chronictabacco smoking on the coronary circulation. J Am Collby the steering committee of the American Heart As­sociation. Circulation 1984; 70: 1114A_1117A24) Hermanson B, Omenn GS, Kronmal RA et al: Bene­

Cardiol 1983; 1: 421_426
8) Kannel WB, Neaton JD, Wentworth D et al: Overall

cial six­year outcome of somking cessation in older

and coronary heart disease mortality rates in relation tomen and women with coronary artery disease, resultsmajor risk factors in 325,348 men screened forfrom CASS registry. N Engl J Med 1988; 319: 1365_1369

MRFIT. Am Heart J 1986; 112: 825_836
9) Kannel WB: Latest perspective on cigarette smoking25) Krumholz HM, Cohen BJ, Tsevat J et al: Cost­eec­

and cardiovascular disease: The Framingham Study. J

tiveness of a smoking cessation program after myo­cardial infarction. J Am Coll Cardiol 1993; 22: 1697_Cardiac Rehabil 1984; 4: 267_277
10) Wilhelmsen L: Coronary heart disease: epidemiology ofsmoking and intervention studies of smoking. Am170226) Inter­society commission for heart disease resources
report: Incidence of coronary attacks among cigaretteHeart J 1988; 115: 24211) Mulcahy R: Inuence of cigarette smoking on morbidi­
ty and mortality after myocardial infarction. Br Heart J

smokers according to subsequent cigarette habit. Cir­
culation 1984; 70: 176A_177AmSuppl An27) plfBXJbVuiKµðÇ¤»f·é1983; 49: 410_41512) Ross R: Atherosclerosis: an inammatory disease. N©v
F¹¾³wïïõÌAP[gÉæéi¦²¸¬ÑDú¹¾ï 1991; 29: 182_185

Engl J Med 1999; 340: 115_12613) Wilhelmsen L: Coronary heart disease: epidemiology of28) Hurt RD, Lauger GG, Oord KP et al: Nicotine­

smoking and intervention studies of somking. Am

replacement therapy with use of a transdermanl nico­Heart J 1988; 115: 242_249

tine patch: a randomized double­blind placebo­con­14) Verheugt FWA: Acute coronary syndromes: interven­

trolled trial. Mayo Clinic Proceedings 1991; 65(12):1529_1537

tions. Lancet 1999; 353mSuppl Un: 16_1915) Goto S, Handa S: Coronary thrombosis: eects of blood29) ¼crVîFS[ÇÌÄ­Eish~C¶w±DS

ow on the mechanism of thrombus formation. Jpn

Ø[Çnre[V}jHeart J 1998; 39: 579_596

ú¶ÈiÄjCæê@KCC1992, p99_114

16) Goto S, Sakai H, Goto M et al: Enhanced shear­induced
platelet aggregation in acute myocardial infarction. Cir­30) ¼crVîC¢vFiÆv[Nj]DProg
Med 2000; 20: 60_63

culation 1999; 99: 608_613

CCHú{zÂíwïêåãACú{ãtïEzÂíêåãæACªæQ B@@ENX